> Research Disclaimer: Semax is a research peptide not approved by the FDA for human therapeutic use. It is approved in Russia as a nootropic and neuroprotective agent. This article summarizes published scientific literature for educational and research purposes only. Not for human use.
What Is Semax?
Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It is derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-7) tetrapeptide Met-Glu-His-Phe, which contains the behavioral activation sequence of ACTH, extended at the C-terminus by a Pro-Gly-Pro tripeptide that confers metabolic stability against enzymatic degradation.
With a molecular weight of approximately 887 Da, Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by N.F. Myasoedov and colleagues in the 1980s. Unlike its parent hormone ACTH, Semax lacks adrenocortical activation properties — it does not stimulate cortisol production — but retains and amplifies ACTH's central nervous system-mediated effects on cognition, learning, memory, and stress adaptation.
Semax is approved in Russia and several post-Soviet countries as Semax nasal drops (0.1% and 1% concentrations) for use as a nootropic, neuroprotective agent, and adjunct treatment for stroke, optic nerve atrophy, and peptic ulcer disease. It is not approved by the FDA, EMA, or comparable Western regulatory agencies.
Structural Features
The C-terminal Pro-Gly-Pro sequence serves two critical functions:
1. Metabolic stability: Pro-Gly-Pro is itself a bioactive tripeptide (the C-terminal Pro-Gly-Pro fragment of alpha-MSH) with independent neuroprotective properties. More importantly, proline flanking reduces proteolytic cleavage, extending the half-life of the combined heptapeptide.
2. Enhanced CNS penetration: The heptapeptide's size and amphiphilicity support nasal epithelial absorption and transcellular transport across the blood-brain barrier via nasal-to-brain routes.
Mechanism of Action
Semax operates through multiple, partially overlapping molecular pathways centered on neurotrophin signaling and neuroprotection:
BDNF Upregulation
The most extensively characterized mechanism of Semax is upregulation of brain-derived neurotrophic factor (BDNF) — the primary neurotrophin governing neuronal survival, synaptic plasticity, long-term potentiation, and neurogenesis. Semax administration in rodent models significantly increases BDNF mRNA expression and BDNF protein concentrations in the hippocampus, frontal cortex, and related limbic structures.
Research by Shadrina et al. (2010) demonstrated that Semax produces a dynamic, time-dependent increase in BDNF gene transcription — with hippocampal BDNF mRNA elevation peaking 24 hours after administration and persisting for several days (PMID: 19662538). Concurrent increases in nerve growth factor (NGF) mRNA were also observed, suggesting Semax activates a broad neurotrophin upregulation program rather than acting narrowly on BDNF alone.
Neurotrophin Receptor Modulation
Beyond increasing neurotrophin ligands, Semax modulates expression of their cognate receptors — including TrkB (the high-affinity BDNF receptor), TrkA (NGF receptor), and p75NTR (pan-neurotrophin receptor). Dmitrieva et al. (2010) demonstrated that Semax and its Pro-Gly-Pro fragment activate the transcription of neurotrophin genes and their receptor genes after cerebral ischemia (PMID: 19633950). This dual upregulation of ligands and receptors amplifies neurotrophic signaling tone.
Ischemia-Induced Neuroprotection
Under ischemic conditions — as occur in stroke — Semax exerts neuroprotective effects by modulating the neurotrophin response to injury, reducing the expression of pro-apoptotic signaling mediators, and enhancing cellular antioxidant defenses. Stavchansky et al. (2011) characterized how Semax and its C-terminal PGP fragment regulate neurotrophin and receptor expression during incomplete global ischemia in rats, finding that the peptide shifts the post-ischemic neurotrophin balance toward survival-promoting signals (PMID: 22295573).
Serotonergic and Dopaminergic Modulation
Semax also affects monoaminergic neurotransmission. Evidence suggests modulation of serotonin turnover and dopamine release in prefrontal and limbic regions — consistent with the observed antidepressant and anxiolytic properties documented in rodent behavioral models.
HIF-1alpha and Angiogenic Signaling
Recent mechanistic research has identified Semax-mediated upregulation of hypoxia-inducible factor 1-alpha (HIF-1alpha) and downstream angiogenic genes under hypoxic conditions — a finding relevant to its neuroprotective activity in ischemic injury models.
Antidepressant and Antistress Properties
Inozemtseva LS et al. (2024) published research in European Journal of Pharmacology demonstrating antidepressant-like and antistress effects of ACTH(4-10) analogs including Semax in male rat behavioral models (PMID: 39442746). These effects appear to be mediated through monoaminergic pathways independently of the HPA axis — as Semax lacks the ACTH cortisol-stimulating sequences.
Key Research Studies
Ischemic Stroke Clinical Application
Gusev EI et al., "The efficacy of Semax in the treatment of patients at different stages of ischemic stroke," Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018 (PMID: 29798983). This Russian clinical study evaluated Semax nasal drops as adjunctive treatment in acute and subacute ischemic stroke patients. Participants treated with Semax demonstrated improved neurological recovery scores and enhanced rehabilitation outcomes compared to standard care alone, consistent with the peptide's preclinical neuroprotective profile.
BDNF and NGF Gene Expression (2010)
Shadrina MI et al., "Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action," Journal of Molecular Neuroscience, 2010 (PMID: 19662538). This foundational study characterized the temporal dynamics of Semax-induced neurotrophin gene expression, establishing the hippocampus as the primary site of BDNF upregulation and demonstrating that the effect is sustained over multiple days — providing a mechanistic basis for Semax's reported cognitive-enhancing effects.
Neurotrophin Activation After Ischemia (2010)
Dmitrieva VG et al., "Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia," Cellular and Molecular Neurobiology, 2010 (PMID: 19633950). This study demonstrated that both intact Semax and its C-terminal Pro-Gly-Pro fragment independently activate neurotrophin gene transcription after cerebral ischemia, suggesting the neuroprotective effects are attributable to both the ACTH-derived sequence and the metabolic stabilizer fragment.
Global Ischemia Neurotrophin Regulation (2011)
Stavchansky VV et al., "Semax and its C-terminal peptide PGP effects on neurotrophin/receptor expression during incomplete global ischemia in rats," Molekulyarnaya Biologiya (Moscow), 2011 (PMID: 22295573). This study extended earlier findings by characterizing the effects of global (rather than focal) ischemia, demonstrating that Semax upregulates neurotrophin survival signaling across multiple brain regions under conditions of diffuse hypoxic injury.
Antidepressant and Antistress Mechanisms (2024)
Inozemtseva LS et al., "Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats," European Journal of Pharmacology, 2024 (PMID: 39442746). This recent publication characterized the antidepressant behavioral profile of Semax in forced swim and tail suspension tests, along with reduced stress reactivity measures, attributing effects to monoaminergic mechanisms distinct from HPA axis modulation.
Research Applications
Ischemic Stroke and Cerebrovascular Research
Semax's most developed research application involves neuroprotection in cerebral ischemia. In Russian clinical practice, Semax nasal drops are used adjunctively in stroke rehabilitation. Researchers use Semax to study the BDNF-mediated component of ischemic neuroprotection and to model post-stroke neuroplasticity.
Neurotrophic Signaling Research
As a reliable BDNF inducer, Semax is used as a pharmacological tool to investigate BDNF-dependent processes including hippocampal neurogenesis, synaptic plasticity, long-term potentiation (LTP), and memory consolidation in rodent models.
Cognitive Enhancement and Learning Research
Behavioral studies consistently demonstrate improved learning acquisition, spatial memory, and attention under Semax administration in normal and cognitively impaired rodents — making it a research tool for mechanistic studies of cognitive enhancement.
Depression and Anxiety Research
The antidepressant and anxiolytic behavioral profiles documented in rodent models position Semax as a research tool for investigating ACTH-fragment-mediated mood regulation and neurotrophic hypotheses of depression.
Optic Nerve Research
Russian clinical trials have examined Semax in optic nerve atrophy, where the peptide's neurotrophic properties may support retinal ganglion cell survival and visual function recovery.
Reconstitution and Storage
For qualified researchers only. Not for human use.
Reconstitution: Semax is most commonly prepared as a nasal drop solution. Research-grade lyophilized Semax is reconstituted in sterile 0.9% sodium chloride (normal saline) or sterile water to the desired concentration. Standard research concentrations range from 0.1% to 1% solutions (1–10 mg/mL). Gentle swirling ensures dissolution without peptide aggregation.
Administration route in research: The primary research administration route for Semax is intranasal — consistent with its approved clinical use and optimized formulation for nasal epithelial absorption and direct nose-to-brain transport. Subcutaneous injection is also used in some preclinical research contexts.
Storage: Lyophilized Semax is stable for 12–24 months at -20°C in a desiccated, light-protected environment. Reconstituted solutions should be refrigerated (2–8°C) and used within 2–4 weeks for maximum potency. Avoid freeze-thaw cycling of reconstituted solutions.
Sourcing Guide
When sourcing Semax for research, prioritize suppliers providing:
- •Third-party HPLC purity certificates (≥98%)
- •Mass spectrometry verification of MEHFPGP sequence and molecular weight (887.02 Da)
- •Proper lyophilization and cold-chain shipping protocols
- •Transparent manufacturing and testing documentation
Compare current Semax research suppliers, pricing, purity standards, and available forms (nasal drops vs. lyophilized powder) on the Peptides.SO Semax comparison page.
Researchers investigating the nootropic peptide space may also be interested in Selank (complementary anxiolytic-nootropic profile), Dihexa, and P21 — which are often studied alongside Semax in cognitive research contexts.
Frequently Asked Questions
How does Semax differ from N-Acetyl Semax or N-Acetyl Semax Amidate?
N-Acetyl Semax is Semax with an acetyl group added to the N-terminus, which is thought to further enhance stability and CNS penetration. N-Acetyl Semax Amidate adds both N-terminal acetylation and C-terminal amidation. These modifications are claimed to increase potency and duration of effect, though direct comparative clinical evidence is limited. Research-grade formulations include all three variants.
Is Semax the same as Selank?
No. While both are Russian-developed research peptides with cognitive and anxiolytic properties, they have distinct sequences, mechanisms, and primary applications. Semax is an ACTH fragment analog with primary BDNF-upregulating and neuroprotective activity. Selank is a tuftsin analog with primary anxiolytic and immunomodulatory activity via GABA and serotonin pathways. They are often studied together as a complementary stack in cognitive and anxiety research.
What distinguishes Semax from racetams or other nootropics?
Unlike racetam-class nootropics, which primarily modulate acetylcholine and glutamate receptor activity, Semax operates through BDNF upregulation and neurotrophic signaling — a mechanistically distinct approach targeting neuronal growth and survival pathways rather than acute receptor modulation. This distinction is significant for researchers interested in neuroplasticity versus acute cognitive enhancement.
Has Semax been studied in humans?
Yes — primarily in Russia. Clinical studies have evaluated Semax in ischemic stroke, optic nerve disorders, peptic ulcer disease, and general cognitive performance. However, these studies generally do not meet Western regulatory standards for randomized controlled trial design and reporting, which is why Semax has not received FDA or EMA approval.
What is the significance of the Pro-Gly-Pro fragment?
The C-terminal Pro-Gly-Pro (PGP) tripeptide is not merely a stability-enhancing moiety. Research has shown that PGP itself is biologically active — stimulating neurotrophin gene expression and exerting neuroprotective effects independently of the ACTH(4-7) portion. This suggests Semax's activity may arise from both its ACTH-derived N-terminal sequence and the C-terminal stabilizer fragment acting in concert.
---
This research profile is for educational purposes only. Semax is not approved by the FDA for human therapeutic use. All research should be conducted by qualified investigators following applicable institutional and regulatory guidelines.